Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases.

The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); Bivigam (immune globulin intravenous) for the treatment of PI; and NABI-HB (hepatitis B immune globulin) to provide enhanced immunity against the hepatitis B virus.

Asceniv was approved by the FDA in April 2019 for PI, also known as primary immune deficiency disease, in adults and children (2 to 17 years of age). Its revenues increased 25.5% year over year to $200.4 million in the first half of 2026. The product accounted for most of ADMA’s revenues in the first half and remained the company’s principal growth driver amid competitive pressure across the broader U.S. immune globulin market.

Asceniv continues to benefit from rising physician adoption, broader prescriber engagement, new patient starts and increased utilization. Growth accelerated during the second quarter, with June marking the strongest sequential monthly increase in Asceniv utilization since the first half of 2024.

During the first half of 2026, ADMA strengthened Asceniv’s real-world evidence base with data from 127 treated patients, most of whom had previously used other immunoglobulin therapies. The analysis showed statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, oral antibiotic use and corticosteroid use following treatment with Asceniv.

The findings have been submitted for presentation at the November 2026 ACAAI Annual Scientific Meeting. The data highlights Asceniv’s potential differentiation in later-line, refractory and medically complex primary immunodeficiency patients.

Management believes the growing evidence base will support broader patient access and payer coverage, while Asceniv’s relatively early market penetration provides further room for growth and supports its confidence in achieving or exceeding 2026 guidance.

ADMA expects revenues in the range of $530 million to $560 million in 2026.

Despite Asceniv’s strong performance, ADMA marginally missed on revenues in the second quarter due to continued decline in Bivigam sales owing to competitive dynamics and pricing pressure within the U.S. immune globulin market.

Competition in the Plasma Therapy Market

ADMA Biologics competes with Grifols GRFS and Takeda TAK for plasma-derived products.

GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. Grifols’ primary plasma products include immunoglobulin (IG), Factor VIII, Alpha 1 (A1PI), and albumin. The company also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX, and plasma thromboplastin component.

Grifols has a strong presence across key segments of the plasma derivatives industry, including A1PI, IG, and albumin, supported by its leading position in plasma collection centers and robust fractionation capacity.

Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard Liquid ECR. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.

ADMA’s Price Performance, Valuation & Estimates

ADMA’s shares have plunged 46.3% year to date against the industry’s growth of 5.6%.

Image Source: Zacks Investment Research

From a valuation perspective, ADMA’s shares currently trade at 3.81X forward sales, higher than its mean of 3.73X and the industry’s 1.95X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved south to 78 cents from 82 cents in the past 60 days, while that for 2027 EPS has declined to 85 cents from 94 cents in the same time frame.

Image Source: Zacks Investment Research

ADMA currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research